Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.

Wu JD, Xu XH, Zhu J, Ding B, Du TX, Gao G, Mao XM, Ye L, Lee KO, Ma JH

Diabetes technology & therapeutics1 Feb 2011Cited by 71 (Europe PMC)

PMID21284481DOI10.1089/dia.2010.0048PepBankPUB-21284481

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced body weight compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced body weight compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 23
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448101
02HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced BMI compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced BMI compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBMI
Study
n = 23
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448102
03HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide improved HbA1c compared with placebo.
In plain wordsIn T2DM patients, exenatide improved HbA1c compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448103
04HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide improved the seven-point glucose profile compared with placebo.
In plain wordsIn T2DM patients, exenatide improved the seven-point glucose profile compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSeven-point glucose profile
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448104
05HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced daily mean glucose compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced average daily blood sugar compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseDaily mean glucose
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Exenatide treatment reduced body weight and body mass index (BMI) and improved HbA1c, the seven-point glucose profile, and daily mean glucose compared with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448105
06HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide limited overall glycemic excursion compared with placebo.
In plain wordsIn T2DM patients, exenatide limited overall blood sugar variation compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseOverall glycemic excursion
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Limited glycemic excursion was found in the E group compared with the P group (P < 0.05), including a smaller SD and postprandial glucose excursion.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448106
07HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced glucose SD compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced blood sugar variation measured by SD compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose standard deviation
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Limited glycemic excursion was found in the E group compared with the P group (P < 0.05), including a smaller SD and postprandial glucose excursion.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448107
08HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced postprandial glucose excursion compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced blood sugar rises after meals compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucose excursion
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
Limited glycemic excursion was found in the E group compared with the P group (P < 0.05), including a smaller SD and postprandial glucose excursion.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448108
09HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide treatment significantly reduced PGF2α.
In plain wordsIn T2DM patients, exenatide treatment significantly reduced the oxidative stress marker PGF2α.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePGF2α
Study
n = 23
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
In addition, the oxidative stress maker PGF2α was significantly reduced by exenatide treatment (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448109
10HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced hs-CRP compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced hs-CRP compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
Decreasehs-CRP
Study
n = 23
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
The inflammatory markers hs-CRP and MCP-1 were also significantly reduced in the E group compared with the P group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448110
11HumanRandomized controlled trialEfficacy outcome
In T2DM patients, exenatide reduced MCP-1 compared with placebo.
In plain wordsIn T2DM patients, exenatide reduced MCP-1 compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseMCP-1
Study
n = 23
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
5 μg twice daily for 4 weeks, then 10 μg twice daily for 12 weeks · 4 weeks at 5 μg twice daily, then 12 weeks at 10 μg twice dailyAs given in this study (human).
Source sentences
Summary
The inflammatory markers hs-CRP and MCP-1 were also significantly reduced in the E group compared with the P group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-three patients with T2DM with inadequate glucose control were randomly divided into two groups: exenatide group (E group) (12 patients, 5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks) and placebo group (P group) (11 patients).
Report a problemFND-2128448111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT02150707

The Differential Effects of Diabetes Therapy on Inflammation

University College Dublinn = 17May 2014 to Dec 2015

Diabetic Nephropathy · Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 18 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.